{
    "clinical_study": {
        "@rank": "52053", 
        "arm_group": {
            "arm_group_label": "aldoxorubicin", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will receive either 50, 100 or 150 mg/m2 (37, 75, and 110 mg/m2 doxorubicin equivalents) by intravenous infusion (IVI) to 10 subjects in each group."
        }, 
        "brief_summary": {
            "textblock": "This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV\n      positive subjects with Kaposi's sarcoma."
        }, 
        "brief_title": "A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Kaposi's Sarcoma", 
            "HIV+", 
            "HIV Positive", 
            "AIDS"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity", 
                "Sarcoma, Kaposi", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label pilot phase 2 study to investigate efficacy, safety, and intratumoral\n      kinetics of aldoxorubicin in HIV-Infected patients with Kaposi's sarcoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u226518 years of age; male or female.\n\n          2. HIV (confirmed by ELISA and western blot) with histologically confirmed KS.\n\n          3. Willing to undergo serial tumor biopsies.\n\n          4. Capable of providing informed consent and complying with trial procedures.\n\n          5. KPS \u226570 (Appendix B)\n\n          6. Easter Cooperative Oncology Group (ECOG) PS 0-2.\n\n          7. Life expectancy \u2265 8 weeks.\n\n          8. Measurable (at accessible site or radiographic) tumor lesions according to ACTG TIS\n             criteria.\n\n          9. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,\n             surgically sterile, or practicing adequate birth control methods) for the duration of\n             the study. (Adequate contraception includes: oral contraception, implanted\n             contraception, intrauterine device implanted for at least 3 months, or barrier method\n             in conjunction with spermicide.)\n\n         10. Women of child bearing potential must have a negative serum or urine pregnancy test\n             at the Screening Visit and be non-lactating.\n\n         11. Geographic accessibility to the site.\n\n        Exclusion Criteria:\n\n          1. Prior exposure to an anthracycline.\n\n          2. Surgery and/or radiation treatment < 4 weeks prior to Randomization.\n\n          3. Exposure to any investigational agent within 30 days of Randomization.\n\n          4. History of other malignancies (except cured basal cell carcinoma, superficial bladder\n             cancer or carcinoma in situ of the cervix) unless documented free of cancer for \u22653\n             years.\n\n          5. Laboratory values: Screening serum creatinine >1.5 \u00d7 upper limit of normal (ULN),\n             alanine aminotransferase (ALT) > 2.5 \u00d7 ULN, total bilirubin >1.5 \u00d7 ULN, absolute\n             neutrophil count (ANC) <1,500/mm3, platelet concentration <75,000/mm3, absolute\n             lymphocyte count <1000/mm3, hematocrit level <25% for females or <27% for males,\n             serum albumin \u22642.5 g/dL.\n\n          6. Evidence of central nervous system (CNS) hemorrhage National Cancer Institute Common\n             Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (published 28 May\n             2009)  grade 2 or greater on baseline MRI.\n\n          7. Clinically evident congestive heart failure (CHF) > class II of the New York Heart\n             Association (NYHA) guidelines.\n\n          8. Current, serious, clinically significant cardiac arrhythmias, defined as the\n             existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown\n             III, IV or V.\n\n          9. History or signs of active coronary artery disease with or without angina pectoris.\n\n         10. Serious myocardial dysfunction defined as ultrasound-determined absolute left\n             ventricular ejection fraction (LVEF) <45% of predicted institutional normal value.\n\n         11. Active, clinically significant serious infection requiring treatment with\n             antibacterial, antiviral (other than antiretroviral therapy), or antifungal therapy.\n\n         12. Major surgery within 4 weeks prior to Randomization.\n\n         13. Any condition that might interfere with the subject's participation in the study or\n             in the evaluation of the study results.\n\n         14. Any condition that is unstable and could jeopardize the subject's participation in\n             the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029430", 
            "org_study_id": "ALDOXORUBICIN-P2-KS-01"
        }, 
        "intervention": {
            "arm_group_label": "aldoxorubicin", 
            "intervention_name": "aldoxorubicin", 
            "intervention_type": "Drug", 
            "other_name": "INNO-206"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HIV +", 
            "HIV positive", 
            "AIDS", 
            "Kaposi's sarcoma", 
            "Sarcoma", 
            "tumor", 
            "cancer"
        ], 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "contact": {
                "email": "ldoyl1@lsuhsc.edu", 
                "last_name": "Lisa Doyle, B.S.", 
                "phone": "504-568-3430"
            }, 
            "contact_backup": {
                "email": "afleur@lsuhsc.edu", 
                "last_name": "Alison Fleury, RN", 
                "phone": "504-826-2188"
            }, 
            "facility": {
                "address": {
                    "city": "New Orleans", 
                    "country": "United States", 
                    "state": "Louisiana", 
                    "zip": "70112"
                }, 
                "name": "Louisiana State University Health Science Center"
            }, 
            "investigator": {
                "last_name": "Chris Parsons, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate the uptake of aldoxorubicin into the tumor and the objective response rate (complete and partial response) using RECIST 1.1 criteria in subjects with HIV-infected with Kaposi's sarcoma", 
                "measure": "Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "description": "To evaluate the safety of ALDOXORUBICIN in this population, assessed by the frequency and severity of adverse events (AEs), abnormal findings on physical examination, laboratory tests, vital signs, echocardiogram (ECHO) evaluations, electrocardiogram (ECG) results, and weight.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029430"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the intratumoral kinetics of ALDOXORUBICIN and related biomarker expression through sequential biopsies of KS skin lesions.", 
                "measure": "Kinetics", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "description": "To determine the change in performance status (PS) as measured by the Karnofsky Performance Status (KPS).", 
                "measure": "Performance Status", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }
        ], 
        "source": "CytRx", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CytRx", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}